市場調査レポート

商品コード

1365704

バイオシミュレーション市場：製品別、用途別、送達モデル別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

Biosimulation Market By Product, By Application, By Delivery model, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年08月01日 | 発行: Allied Market Research

| ページ情報: 英文 435 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

バイオシミュレーション市場の2022年の市場規模は25億米ドルで、2032年には106億米ドルに達し、2023年から2032年までのCAGRは15.8%で成長すると予測されています。

ヒトの生物学にとって不可欠な生物学的プロセスをコンピュータ支援によってシミュレーションすることは、バイオシミュレーションとして知られています。バイオシミュレーションの目的は、生体系のダイナミクスと挙動をモデルに基づいて予測することです。シミュレーションモデルは、生体システムに関する知識を数式に変換します。医薬品開発プロセスの初期段階では、最初の分子が製造される前であっても、シミュレーションモデルを使用してあらゆる仮説を検証し、その機能を最適化するために製品を変更したり、所定の薬剤が医薬品として機能する可能性を推定したりすることが想定されます。シミュレーションモデルは、効果的な試験プロトコルを定義し、試験から得られた情報が一貫していることを確認するための手段として使用されることが期待されています。

新薬の前臨床試験、リード化合物の同定と最適化、標的の同定と検証は、医薬品の研究開発においてバイオシミュレーションが利用されている主な分野です。バイオシミュレーションは、生物学、化学、薬理学の原理を独自のアルゴリズムに適用することで、医薬品や疾患が体内でどのように作用するかを正確に予測することを目的とした「仮想」医薬品試験のバックボーンを形成しています。さらに、この仕事には、薬物相互作用、安全な投与、毒性予測などに関する重要な洞察の収集も含まれます。

世界のバイオシミュレーション市場の成長を促進する主な要因としては、創薬・市場開拓需要の増加、個別化医薬品のニーズの高まり、バイオシミュレーションソフトウェアおよびデバイスの技術進歩の急増などが挙げられます。例えば、バイオシミュレーションの世界的リーダーであるCertara社は、2022年6月に免疫原性（IG）、免疫腫瘍学（IO）、ワクチンシミュレーターの新バージョンをリリースし、薬剤の作用予測や新規生物学的治療法の開発における重要な疑問点の解決に役立てています。

さらに、新薬治療法開発のための製薬・バイオテクノロジー業界における研究開発投資の増加や、がん、糖尿病、アルツハイマー病、心血管疾患、腎臓疾患などの慢性疾患の有病率の増加が、バイオシミュレーションソフトウェアの需要を増大させ、市場の成長を促進する主な要因となっています。また、創薬・研究開発コストの削減に対する需要の高まりや、創薬・研究開発のための医薬品開発業務受託機関（CRO）や学術研究機関におけるバイオシミュレーションソフトウェアの普及率の上昇が、バイオシミュレーション市場の成長を後押しする主な要因となっています。

しかし、標準化されたフォーマット、プロトコル、異なるシミュレーションプラットフォーム間の相互運用性が欠如していること、研究者やヘルスケア専門家のバイオシミュレーション技術に対する認識や教育が限定的であることが、バイオシミュレーション市場の成長を抑制しています。その一方で、小児の医薬品開発における個別化医療とバイオシミュレーションソリューションの用途の拡大と利用の増加は、バイオシミュレーション市場に今後数年間のさらなる成長機会をもたらすと予想されます。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - バイオシミュレーションソフトウェアの採用拡大
  - バイオシミュレーションソフトウェアの技術的進歩
  - 創薬・開発コスト削減のための需要増加
- 抑制要因
  - 標準化と相互運用性の欠如
- 機会
  - バイオシミュレーションアプリケーションの拡大と個別化医療に対する需要の増加
COVID-19市場への影響分析

第4章バイオシミュレーション市場：製品別

概要
ソフトウェア
サービス

第5章 BIOSIMULATION市場：アプリケーション別

概要
医薬品開発
創薬
その他

第6章 BIOSIMULATION市場：送達モデル別

概要
サブスクリプションモデル
所有モデル

第7章 BIOSIMULATION市場：エンドユーザー別

概要
製薬企業およびバイオテクノロジー企業
CRO（医薬品開発業務受託機関）
学術・研究機関

第8章 BIOSIMULATION市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- オーストラリア
- インド
- 韓国
- その他
ラテンアメリカ
- ラテンアメリカ
- 中東
- アフリカ

第9章競合情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第10章企業プロファイル

Certara, Inc.
Dassault Systemes
Simulations Plus, Inc.
Genedata AG
SimBioSys
Physiomics Plc
INOSIM Software GmbH
VeriSIM Life
Schrodinger, Inc.
Cadence Design Systems, Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. BIOSIMULATION MARKET FOR SOFTWARE, BY REGION, 2022-2032 ($MILLION)
TABLE 03. BIOSIMULATION MARKET FOR SERVICES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 05. BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY REGION, 2022-2032 ($MILLION)
TABLE 06. BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY REGION, 2022-2032 ($MILLION)
TABLE 07. BIOSIMULATION MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 09. BIOSIMULATION MARKET FOR SUBSCRIPTION MODEL, BY REGION, 2022-2032 ($MILLION)
TABLE 10. BIOSIMULATION MARKET FOR OWNERSHIP MODEL, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 12. BIOSIMULATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATION (CROS), BY REGION, 2022-2032 ($MILLION)
TABLE 14. BIOSIMULATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2022-2032 ($MILLION)
TABLE 15. BIOSIMULATION MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 21. U.S. BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 22. U.S. BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 23. U.S. BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 24. U.S. BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 25. CANADA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 26. CANADA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. CANADA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 28. CANADA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. MEXICO BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 30. MEXICO BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. MEXICO BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 32. MEXICO BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. EUROPE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 34. EUROPE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. EUROPE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 36. EUROPE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 37. EUROPE BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 38. GERMANY BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 39. GERMANY BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 40. GERMANY BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 41. GERMANY BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. FRANCE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 43. FRANCE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. FRANCE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 45. FRANCE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 46. UK BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 47. UK BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. UK BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 49. UK BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 50. ITALY BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 51. ITALY BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. ITALY BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 53. ITALY BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. SPAIN BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 55. SPAIN BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 56. SPAIN BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 57. SPAIN BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. REST OF EUROPE BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 59. REST OF EUROPE BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. REST OF EUROPE BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 61. REST OF EUROPE BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. ASIA-PACIFIC BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 63. ASIA-PACIFIC BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. ASIA-PACIFIC BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 65. ASIA-PACIFIC BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 67. JAPAN BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 68. JAPAN BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 69. JAPAN BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 70. JAPAN BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 71. CHINA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 72. CHINA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 73. CHINA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 74. CHINA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 75. AUSTRALIA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 76. AUSTRALIA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 77. AUSTRALIA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 78. AUSTRALIA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 79. INDIA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 80. INDIA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. INDIA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 82. INDIA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. SOUTH KOREA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 84. SOUTH KOREA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH KOREA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 86. SOUTH KOREA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 87. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 88. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 90. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 91. LAMEA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 92. LAMEA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 93. LAMEA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 94. LAMEA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 95. LAMEA BIOSIMULATION MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 96. LATIN AMERICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 97. LATIN AMERICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 98. LATIN AMERICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 99. LATIN AMERICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 100. MIDDLE EAST BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 101. MIDDLE EAST BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 102. MIDDLE EAST BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 103. MIDDLE EAST BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 104. AFRICA BIOSIMULATION MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 105. AFRICA BIOSIMULATION MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 106. AFRICA BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022-2032 ($MILLION)
TABLE 107. AFRICA BIOSIMULATION MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 108. CERTARA, INC.: KEY EXECUTIVES
TABLE 109. CERTARA, INC.: COMPANY SNAPSHOT
TABLE 110. CERTARA, INC.: SERVICE SEGMENTS
TABLE 111. CERTARA, INC.: PRODUCT PORTFOLIO
TABLE 112. CERTARA, INC.: KEY STRATERGIES
TABLE 113. DASSAULT SYSTEMES: KEY EXECUTIVES
TABLE 114. DASSAULT SYSTEMES: COMPANY SNAPSHOT
TABLE 115. DASSAULT SYSTEMES: PRODUCT SEGMENTS
TABLE 116. DASSAULT SYSTEMES: PRODUCT PORTFOLIO
TABLE 117. SIMULATIONS PLUS, INC.: KEY EXECUTIVES
TABLE 118. SIMULATIONS PLUS, INC.: COMPANY SNAPSHOT
TABLE 119. SIMULATIONS PLUS, INC.: SERVICE SEGMENTS
TABLE 120. SIMULATIONS PLUS, INC.: PRODUCT PORTFOLIO
TABLE 121. SIMULATIONS PLUS, INC.: KEY STRATERGIES
TABLE 122. GENEDATA AG: KEY EXECUTIVES
TABLE 123. GENEDATA AG: COMPANY SNAPSHOT
TABLE 124. GENEDATA AG: PRODUCT SEGMENTS
TABLE 125. GENEDATA AG: PRODUCT PORTFOLIO
TABLE 126. GENEDATA AG: KEY STRATERGIES
TABLE 127. SIMBIOSYS: KEY EXECUTIVES
TABLE 128. SIMBIOSYS: COMPANY SNAPSHOT
TABLE 129. SIMBIOSYS: SERVICE SEGMENTS
TABLE 130. SIMBIOSYS: PRODUCT PORTFOLIO
TABLE 131. PHYSIOMICS PLC: KEY EXECUTIVES
TABLE 132. PHYSIOMICS PLC: COMPANY SNAPSHOT
TABLE 133. PHYSIOMICS PLC: SERVICE SEGMENTS
TABLE 134. PHYSIOMICS PLC: PRODUCT PORTFOLIO
TABLE 135. INOSIM SOFTWARE GMBH: KEY EXECUTIVES
TABLE 136. INOSIM SOFTWARE GMBH: COMPANY SNAPSHOT
TABLE 137. INOSIM SOFTWARE GMBH: SERVICE SEGMENTS
TABLE 138. INOSIM SOFTWARE GMBH: PRODUCT PORTFOLIO
TABLE 139. VERISIM LIFE: KEY EXECUTIVES
TABLE 140. VERISIM LIFE: COMPANY SNAPSHOT
TABLE 141. VERISIM LIFE: SERVICE SEGMENTS
TABLE 142. VERISIM LIFE: PRODUCT PORTFOLIO
TABLE 143. VERISIM LIFE: KEY STRATERGIES
TABLE 144. SCHRODINGER, INC.: KEY EXECUTIVES
TABLE 145. SCHRODINGER, INC.: COMPANY SNAPSHOT
TABLE 146. SCHRODINGER, INC.: SERVICE SEGMENTS
TABLE 147. SCHRODINGER, INC.: PRODUCT PORTFOLIO
TABLE 148. SCHRODINGER, INC.: KEY STRATERGIES
TABLE 149. CADENCE DESIGN SYSTEMS, INC.: KEY EXECUTIVES
TABLE 150. CADENCE DESIGN SYSTEMS, INC.: COMPANY SNAPSHOT
TABLE 151. CADENCE DESIGN SYSTEMS, INC.: SERVICE SEGMENTS
TABLE 152. CADENCE DESIGN SYSTEMS, INC.: PRODUCT PORTFOLIO
TABLE 153. CADENCE DESIGN SYSTEMS, INC.: KEY STRATERGIES

LIST OF FIGURES

FIGURE 01. BIOSIMULATION MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF BIOSIMULATION MARKET,2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN BIOSIMULATION MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW INTENSITY OF RIVALRY
FIGURE 08. LOW BARGAINING POWER OF BUYERS
FIGURE 09. GLOBAL BIOSIMULATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 10. BIOSIMULATION MARKET, BY PRODUCT, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SOFTWARE, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SERVICES, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. BIOSIMULATION MARKET, BY APPLICATION, 2022(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR DRUG DEVELOPMENT, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR DRUG DISCOVERY, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. BIOSIMULATION MARKET, BY DELIVERY MODEL, 2022(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR SUBSCRIPTION MODEL, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR OWNERSHIP MODEL, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. BIOSIMULATION MARKET, BY END USER, 2022(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR CONTRACT RESEARCH ORGANIZATION (CROS), BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF BIOSIMULATION MARKET FOR ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. BIOSIMULATION MARKET BY REGION, 2022(%)
FIGURE 25. U.S. BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 26. CANADA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 27. MEXICO BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 28. GERMANY BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 29. FRANCE BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 30. UK BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 31. ITALY BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 32. SPAIN BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 33. REST OF EUROPE BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 34. JAPAN BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 35. CHINA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 36. AUSTRALIA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 37. INDIA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 38. SOUTH KOREA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 39. REST OF ASIA-PACIFIC BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 40. LATIN AMERICA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 41. MIDDLE EAST BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 42. AFRICA BIOSIMULATION MARKET, 2022-2032 ($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR (2020-2023)
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT (2020-2023)
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY (2020-2023)
FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47. COMPETITIVE DASHBOARD
FIGURE 48. COMPETITIVE HEATMAP: BIOSIMULATION MARKET
FIGURE 49. TOP PLAYER POSITIONING, 2022
FIGURE 50. CERTARA, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 51. CERTARA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. CERTARA, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. DASSAULT SYSTEMES: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 54. DASSAULT SYSTEMES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. DASSAULT SYSTEMES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 56. SIMULATIONS PLUS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. SIMULATIONS PLUS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 58. SIMULATIONS PLUS, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 59. PHYSIOMICS PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 60. SCHRODINGER, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 61. SCHRODINGER, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. SCHRODINGER, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 63. CADENCE DESIGN SYSTEMS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 64. CADENCE DESIGN SYSTEMS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 65. CADENCE DESIGN SYSTEMS, INC.: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A00288

According to a new report published by Allied Market Research, titled, "Biosimulation Market," The biosimulation market was valued at $2.5 billion in 2022, and is estimated to reach $10.6 billion by 2032, growing at a CAGR of 15.8% from 2023 to 2032. The computer-assisted simulation of biological processes that are essential to human biology is known as biosimulation. The goal of biosimulation is to offer model-based predictions of the dynamics and behavior of a biological system. A simulation model translates the knowledge about the biological system into mathematical equations. In the initial stage of the drug development process, one is anticipated to use the simulation model to test any hypothesis and change the product in order to optimize its function or estimate the chances that a given agent is projected to function as a drug, even before the first molecule is produced. The simulation model is anticipated to be used as a vehicle to define an effective test protocol and to check that information obtained from tests is consistent.

Pre-clinical testing of novel medicines, lead identification and optimization, target identification and validation are some primary areas where biosimulation is being used in drug R&D. Biosimulation forms the backbone of "virtual" drug trials, whose aim is to accurately predict the way medicines and diseases behave in the body by applying principles from biology, chemistry, and pharmacology with proprietary algorithms. In addition, this work includes gathering critical insights concerning drug interactions, safe dosing, toxicity predictions, and more.

Major factors that drive the growth of the global biosimulation market include an increase in demand for drug discovery and development, rise in need for personalized medicines, and surge in technological advancement in biosimulation software and devices. For instance, in June 2022, Certara, a global leader in biosimulation, released the new versions of immunogenicity (IG), immuno-oncology (IO) and vaccine simulators to help predict how drugs work and address key questions in the development of novel biologic therapies.

Furthermore, increase in R&D investment in pharmaceutical & biotechnology industries for the development of novel drug therapies and increase in prevalence of chronic diseases such as cancer, diabetes, Alzheimer's, cardiovascular disease, kidney disorders, and various others are the major factors that increase the demand for biosimulation software and hence propel the growth of the market. In addition, rise in demand to reduce drug discovery and development costs and increase in penetration of biosimulation software in contract research organization (CROs) and academic research institutes for drug discovery and development are the major factors that boost the growth of the biosimulation market.

However, the lack of standardized formats, protocols, and interoperability between different simulation platforms and limited awareness and education about biosimulation techniques among researchers and healthcare professionals restrain the growth of the biosimulation market. On the contrary, the expanding applications and increased use of personalized medicine and biosimulation solutions for pediatric drug development are expected to provide additional opportunities for the biosimulation market to grow in the coming years.

The global biosimulation market is segmented into product, application, end user, and region. On the basis of product, the market is bifurcated into software and services. On the basis of delivery model, the market is segmented into subscription model and ownership model. On the basis of application, it is segregated into drug development, drug discovery and others. On the basis of end user, it is segmented into pharmaceutical and biotechnology companies, contract research organization (CROs) and academic and research institutes. On the basis of region, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The major players profiled in the report are Dassault Systemes, VeriSIM Life, Certara Inc, Genedata AG, SimBioSys, Physiomics PLC, INOSIM Software GmbH, Schrodinger, Inc. Simulation Plus Inc, and Cadence Design Systems, Inc. The key players such as Simulation Plus Inc, Cadence Design Systems Inc, VeriSIM Life, Certara Inc, Schrodinger Inc, and Genedata AG have adopted product launch, acquisition, collaboration, partnership, and business expansion as major developmental strategies to improve the product portfolio of the biosimulation market.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biosimulation market analysis from 2022 to 2032 to identify the prevailing biosimulation market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the biosimulation market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global biosimulation market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

Market share analysis of players by products/segments
New Product Development/ Product Matrix of Key Players
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Average Selling Price Analysis / Price Point Analysis
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Product

Software
Services

By Application

Drug Development
Drug Discovery
Others

By Delivery model

Subscription Model
Ownership Model

By End User

Pharmaceutical and Biotechnology Companies
Contract Research Organization (CROs)
Academic and Research Institutes

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Latin America
- Middle East
- Africa

Key Market Players:

SimBioSys
Physiomics Plc
Genedata AG
Simulations Plus, Inc.
Cadence Design Systems, Inc.
Certara, Inc.
VeriSIM Life
Schrodinger, Inc.
Dassault Systemes
INOSIM Software GmbH

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Growth in adoption of biosimulation software
  - 3.4.1.2. Technological advancements in biosimulation software
  - 3.4.1.3. Increase in demand to curtail drug discovery and development costs

3.4.2. Restraints
- 3.4.2.1. Lack of standardization and interoperability

3.4.3. Opportunities
- 3.4.3.1. Expansion of applications of biosimulation and increase in demand for personalized medicine.

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: BIOSIMULATION MARKET, BY PRODUCT

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Software
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Services
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: BIOSIMULATION MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Drug Development
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Drug Discovery
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: BIOSIMULATION MARKET, BY DELIVERY MODEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Subscription Model
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Ownership Model
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country

CHAPTER 7: BIOSIMULATION MARKET, BY END USER

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Pharmaceutical and Biotechnology Companies
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Contract Research Organization (CROs)
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Academic and Research Institutes
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country

CHAPTER 8: BIOSIMULATION MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key market trends, growth factors and opportunities
- 8.2.2. Market size and forecast, by Product
- 8.2.3. Market size and forecast, by Application
- 8.2.4. Market size and forecast, by Delivery model
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Market size and forecast, by Product
  - 8.2.6.1.2. Market size and forecast, by Application
  - 8.2.6.1.3. Market size and forecast, by Delivery model
  - 8.2.6.1.4. Market size and forecast, by End User
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Market size and forecast, by Product
  - 8.2.6.2.2. Market size and forecast, by Application
  - 8.2.6.2.3. Market size and forecast, by Delivery model
  - 8.2.6.2.4. Market size and forecast, by End User
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Market size and forecast, by Product
  - 8.2.6.3.2. Market size and forecast, by Application
  - 8.2.6.3.3. Market size and forecast, by Delivery model
  - 8.2.6.3.4. Market size and forecast, by End User
8.3. Europe
- 8.3.1. Key market trends, growth factors and opportunities
- 8.3.2. Market size and forecast, by Product
- 8.3.3. Market size and forecast, by Application
- 8.3.4. Market size and forecast, by Delivery model
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Market size and forecast, by Product
  - 8.3.6.1.2. Market size and forecast, by Application
  - 8.3.6.1.3. Market size and forecast, by Delivery model
  - 8.3.6.1.4. Market size and forecast, by End User
  - 8.3.6.2. France
  - 8.3.6.2.1. Market size and forecast, by Product
  - 8.3.6.2.2. Market size and forecast, by Application
  - 8.3.6.2.3. Market size and forecast, by Delivery model
  - 8.3.6.2.4. Market size and forecast, by End User
  - 8.3.6.3. UK
  - 8.3.6.3.1. Market size and forecast, by Product
  - 8.3.6.3.2. Market size and forecast, by Application
  - 8.3.6.3.3. Market size and forecast, by Delivery model
  - 8.3.6.3.4. Market size and forecast, by End User
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Market size and forecast, by Product
  - 8.3.6.4.2. Market size and forecast, by Application
  - 8.3.6.4.3. Market size and forecast, by Delivery model
  - 8.3.6.4.4. Market size and forecast, by End User
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Market size and forecast, by Product
  - 8.3.6.5.2. Market size and forecast, by Application
  - 8.3.6.5.3. Market size and forecast, by Delivery model
  - 8.3.6.5.4. Market size and forecast, by End User
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Market size and forecast, by Product
  - 8.3.6.6.2. Market size and forecast, by Application
  - 8.3.6.6.3. Market size and forecast, by Delivery model
  - 8.3.6.6.4. Market size and forecast, by End User
8.4. Asia-Pacific
- 8.4.1. Key market trends, growth factors and opportunities
- 8.4.2. Market size and forecast, by Product
- 8.4.3. Market size and forecast, by Application
- 8.4.4. Market size and forecast, by Delivery model
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Market size and forecast, by Product
  - 8.4.6.1.2. Market size and forecast, by Application
  - 8.4.6.1.3. Market size and forecast, by Delivery model
  - 8.4.6.1.4. Market size and forecast, by End User
  - 8.4.6.2. China
  - 8.4.6.2.1. Market size and forecast, by Product
  - 8.4.6.2.2. Market size and forecast, by Application
  - 8.4.6.2.3. Market size and forecast, by Delivery model
  - 8.4.6.2.4. Market size and forecast, by End User
  - 8.4.6.3. Australia
  - 8.4.6.3.1. Market size and forecast, by Product
  - 8.4.6.3.2. Market size and forecast, by Application
  - 8.4.6.3.3. Market size and forecast, by Delivery model
  - 8.4.6.3.4. Market size and forecast, by End User
  - 8.4.6.4. India
  - 8.4.6.4.1. Market size and forecast, by Product
  - 8.4.6.4.2. Market size and forecast, by Application
  - 8.4.6.4.3. Market size and forecast, by Delivery model
  - 8.4.6.4.4. Market size and forecast, by End User
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Market size and forecast, by Product
  - 8.4.6.5.2. Market size and forecast, by Application
  - 8.4.6.5.3. Market size and forecast, by Delivery model
  - 8.4.6.5.4. Market size and forecast, by End User
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Market size and forecast, by Product
  - 8.4.6.6.2. Market size and forecast, by Application
  - 8.4.6.6.3. Market size and forecast, by Delivery model
  - 8.4.6.6.4. Market size and forecast, by End User
8.5. LAMEA
- 8.5.1. Key market trends, growth factors and opportunities
- 8.5.2. Market size and forecast, by Product
- 8.5.3. Market size and forecast, by Application
- 8.5.4. Market size and forecast, by Delivery model
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Latin America
  - 8.5.6.1.1. Market size and forecast, by Product
  - 8.5.6.1.2. Market size and forecast, by Application
  - 8.5.6.1.3. Market size and forecast, by Delivery model
  - 8.5.6.1.4. Market size and forecast, by End User
  - 8.5.6.2. Middle East
  - 8.5.6.2.1. Market size and forecast, by Product
  - 8.5.6.2.2. Market size and forecast, by Application
  - 8.5.6.2.3. Market size and forecast, by Delivery model
  - 8.5.6.2.4. Market size and forecast, by End User
  - 8.5.6.3. Africa
  - 8.5.6.3.1. Market size and forecast, by Product
  - 8.5.6.3.2. Market size and forecast, by Application
  - 8.5.6.3.3. Market size and forecast, by Delivery model
  - 8.5.6.3.4. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. Certara, Inc.
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Business performance
- 10.1.0. Key strategic moves and developments
10.2. Dassault Systemes
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
- 10.2.6. Business performance
10.3. Simulations Plus, Inc.
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Business performance
- 10.3.0. Key strategic moves and developments
10.4. Genedata AG
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.0. Key strategic moves and developments
10.5. SimBioSys
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
10.6. Physiomics Plc
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Business performance
10.7. INOSIM Software GmbH
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
10.8. VeriSIM Life
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
- 10.8.0. Key strategic moves and developments
10.9. Schrodinger, Inc.
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Business performance
- 10.9.0. Key strategic moves and developments
10.10. Cadence Design Systems, Inc.
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio
- 10.10.6. Business performance
- 10.10.0. Key strategic moves and developments

バイオシミュレーション市場：製品別、用途別、送達モデル別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

Biosimulation Market By Product, By Application, By Delivery model, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章バイオシミュレーション市場：製品別

第5章 BIOSIMULATION市場：アプリケーション別

第6章 BIOSIMULATION市場：送達モデル別

第7章 BIOSIMULATION市場：エンドユーザー別

第8章 BIOSIMULATION市場：地域別

第9章競合情勢

第10章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Product

By Application

By Delivery model

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: BIOSIMULATION MARKET, BY PRODUCT

CHAPTER 5: BIOSIMULATION MARKET, BY APPLICATION

CHAPTER 6: BIOSIMULATION MARKET, BY DELIVERY MODEL

CHAPTER 7: BIOSIMULATION MARKET, BY END USER

CHAPTER 8: BIOSIMULATION MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

バイオシミュレーション市場：製品別、用途別、送達モデル別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

Biosimulation Market By Product, By Application, By Delivery model, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 バイオシミュレーション市場：製品別

第5章 BIOSIMULATION市場：アプリケーション別

第6章 BIOSIMULATION市場：送達モデル別

第7章 BIOSIMULATION市場：エンドユーザー別

第8章 BIOSIMULATION市場：地域別

第9章 競合情勢

第10章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Product

By Application

By Delivery model

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: BIOSIMULATION MARKET, BY PRODUCT

CHAPTER 5: BIOSIMULATION MARKET, BY APPLICATION

CHAPTER 6: BIOSIMULATION MARKET, BY DELIVERY MODEL

CHAPTER 7: BIOSIMULATION MARKET, BY END USER

CHAPTER 8: BIOSIMULATION MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章バイオシミュレーション市場：製品別

第9章競合情勢

第10章企業プロファイル